Neuberger Berman Group
RCUS icon

Neuberger Berman Group’s Arcus Biosciences RCUS Stock Holding History

Neuberger Berman Group’s Portfolio RCUS Stock Details RCUS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q4 		– Sell
-7,837
Closed -$212K – 1858
2022
Q3 		$212K Sell
7,837
-3,797
-33% -$100K ﹤0.01% 1711
2022
Q2 		$300K Buy
+11,634
New +$285K ﹤0.01% 1643

Other funds holding RCUS

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
PHS
PFM Health Sciences San Francisco, California $1.1B AUM 57.92% 1-Year Est. Return
OCA
Octagon Capital Advisors New York $904M AUM 737.04% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
IFA
Invus Financial Advisors New York $89.2M AUM 10.79% 1-Year Est. Return
BC
Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return
PAMS
Pictet Asset Management (Switzerland) Geneva 73, Switzerland $84.3B AUM 26.5% 1-Year Est. Return

Neuberger Berman Group's RCUS Position: Q4 2022 in Review

Neuberger Berman Group sold out of Arcus Biosciences (RCUS) in Q4 2022, closing a stake of 7,837 shares — an estimated $212K sold.

Neuberger Berman Group first reported a position in RCUS in Q2 2022 and held it in 2 quarters. The position peaked at $300K in Q2 2022. 200 funds tracked by Wall St. Rank hold RCUS as of Q4 2022.

  • Neuberger Berman Group reported no remaining Arcus Biosciences position as of Q4 2022 after selling out during the quarter.
  • Neuberger Berman Group sold 7,837 Arcus Biosciences shares in Q4 2022, an estimated $212K.
  • Neuberger Berman Group first reported a position in Arcus Biosciences in Q2 2022 and held it in 2 quarters.
  • Neuberger Berman Group's Arcus Biosciences position peaked at $300K in Q2 2022.
  • 200 funds tracked by Wall St. Rank held Arcus Biosciences as of Q4 2022.

Based on Neuberger Berman Group's 13F filing for Q4 2022, filed 13 Feb 2023.